Cargando…

Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People’s Republic of China

BACKGROUND: The aims of this analysis were to identify factors associated with early response (at 4 weeks) to olanzapine treatment and to assess whether early response is associated with better longer-term outcomes for patients with schizophrenia in the People’s Republic of China. METHODS: A post ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Wenyu, Montgomery, William, Kadziola, Zbigniew, Liu, Li, Xue, Haibo, Stensland, Michael D, Treuer, Tamas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037300/ https://www.ncbi.nlm.nih.gov/pubmed/24876779 http://dx.doi.org/10.2147/NDT.S59468

Ejemplares similares

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
por: Montgomery, William, et al.
Publicado: (2014)

The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy
por: Montgomery, William, et al.
Publicado: (2013)

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine
por: Montgomery, William, et al.
Publicado: (2015)

Clinical utility of orally disintegrating olanzapine in Chinese patients with schizophrenia: a review of effectiveness, patient preference, adherence, and other properties
por: Zhao, Jingping, et al.
Publicado: (2014)

Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
por: Xue, Hai Bo Haber, et al.
Publicado: (2014)

Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
por: Wu, Jing, et al.
Publicado: (2015)

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder
por: Novick, Diego, et al.
Publicado: (2017)

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
por: Montgomery, William, et al.
Publicado: (2012)

The potential role of appetite in predicting weight changes during treatment with olanzapine
por: Case, Michael, et al.
Publicado: (2010)

An In Vitro Analysis of Disintegration Times of Different Formulations of Olanzapine Orodispersible Tablet: A Preliminary Report
por: Hobbs, David, et al.
Publicado: (2013)

A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia
por: Singh, Anmol, et al.
Publicado: (2018)

Immunosuppressant-Associated Neurotoxicity Responding to Olanzapine
por: Bourgeois, James A., et al.
Publicado: (2014)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Ye, Wenyu, et al.
Publicado: (2012)

Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
por: Correll, Christoph U, et al.
Publicado: (2023)

Sexual dysfunction in male schizophrenia remitted patients treated with risperidone and olanzapine
Publicado: (2022)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick, Diego, et al.
Publicado: (2016)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine
por: Mier, Daniela, et al.
Publicado: (2018)

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
por: Lipkovich, Ilya, et al.
Publicado: (2008)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China
por: He, Xiaoning, et al.
Publicado: (2015)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
por: Bitter, Istvan, et al.
Publicado: (2010)

Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People’s Republic of China
por: Li, Cheng-Rang, et al.
Publicado: (2015)

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
por: Ye, Wenyu, et al.
Publicado: (2012)

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia
por: Liang, Lingzhi, et al.
Publicado: (2022)

Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia
por: Katshu, Mohammad Zia Ul Haq, et al.
Publicado: (2018)

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
por: Ünsal, Cüneyt, et al.
Publicado: (2013)

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study
por: Zhao, Lei, et al.
Publicado: (2023)

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
por: Novick, Diego, et al.
Publicado: (2015)

Intramuscular Olanzapine – a UK case series of early cases
por: Bushe, Chris J, et al.
Publicado: (2007)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
por: Shoja Shafti, Saeed, et al.
Publicado: (2014)

Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia
por: Tajiri, Misuzu, et al.
Publicado: (2018)

Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
por: Hindmarsh, Jonathan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3sev6l7b7rbcpfb3p03loa337